By Len Zehr Advaxis (NASDAQ:ADXS) hopes to begin a registration trial before the end of the year with its next-generation immunotherapy, ADXS-HPV, for the treatment of invasive cervical cancer. “We are pleased with the...
Tag - invasive cervical cancer
